|
**Overview**: NRAS Mutation Panel**Introduction**: The NRAS Mutation Panel is a diagnostic tool designed to detect NRAS mutations using FFPE tissue. In India, NRAS mutations occur in ~5-15 percent of melanomas, ~5-10 percent of colorectal cancers, and ~5 percent of lung adenocarcinomas, predicting resistance to EGFR inhibitors in CRC and poor prognosis in melanoma. High morbidity from under-testing in rural/low-SES cancer patients, limited molecular pathology labs, delayed appropriate therapy (avoiding cetuximab in NRAS-mutant CRC) leading to treatment failure or progression. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for NRAS codons 12, 13, and 61 over 1-2 days with high sensitivity, valuable for precision oncology in advanced solid tumors. This diagnostic falls under genetic cancer screening and targets patients with melanoma, CRC, or NSCLC, addressing accurate detection to guide alternative regimens or clinical trials. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise mutation profiling and improving cancer outcomes. Its FFPE-based approach ensures reliable hotspot mutation detection.**Other Names**: NRAS Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: NRAS testing standard in melanoma/CRC since 2010s; in India, expanding in precision oncology.**Purpose**: The test assesses 3 parameters including NRAS Codon 12 to guide mutation detection, predict therapy resistance, inform targeted treatment.**Test Parameters**: 1. NRAS Codon 12, 2. NRAS Codon 13, 3. NRAS Codon 61.**Pretest Condition**: No fasting required; patients should have confirmed malignancy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on tumor type, stage, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected mutation including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive NRAS mutation predicts resistance/prognosis, necessitating specialist input.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: KRAS/BRAF, full NGS panel for confirmation.**Test Limitations**: Detects common codons; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Cancer Studies India 2023. |
